Baidu
map

Biomed Pharmacother:地塞米松通过ROS-PI3K/AKT/GSK3β信号通路诱导成骨细胞凋亡

2019-02-04 MedSci MedSci原创

成骨细胞在成骨和预防骨坏死过程中起重要作用。地塞米松(Dex)是一种糖皮质激素(GCs),可诱导成骨细胞凋亡,并导致非创伤性骨坏死的发生。本研究旨在探讨磷脂酰肌醇3-激酶/蛋白激酶3(PI3K/AKT)和糖原合成酶激酶3β(GSK3β)对Dex诱导的成骨细胞凋亡的影响。使用细胞计数试剂盒-8(CCK-8)测定,5-溴-2'-脱氧尿苷(BrdU)掺入测定法,FITC-Annexin V / PI染色

成骨细胞在成骨和预防骨坏死过程中起重要作用。地塞米松(Dex)是一种糖皮质激素(GCs),可诱导成骨细胞凋亡,并导致非创伤性骨坏死的发生。本研究旨在探讨磷脂酰肌醇3-激酶/蛋白激酶3(PI3K/AKT)和糖原合成酶激酶3β(GSK3β)对Dex诱导的成骨细胞凋亡的影响。

使用细胞计数试剂盒-8(CCK-8)测定,5-溴-2'-脱氧尿苷(BrdU)掺入测定法,FITC-Annexin V / PI染色和蛋白质印迹分别检测Dex处理后原代成骨细胞和前成骨细胞MC3T3-E1细胞的可靠性,增殖和凋亡。使用2',7'-二氯二氢荧光素二乙酸酯(DCFH-DA)染色以测量Dex处理后的细胞内活性氧(ROS)水平。在该研究中,N-乙酰基-1-半胱氨酸(NAC)用作ROS清除剂。采用Western blotting和qRT-PCR分析Dex处理后成骨细胞和MC3T3-E1细胞中PI3K/AKT和GSK3β的表达。然后探讨了GSK3β敲低对Dex诱导的成骨细胞凋亡的影响。碱性磷酸酶(ALP)活性测定用于检测Dex在调节ALP活性中的作用。

结果显示,Dex显著抑制成骨细胞和MC3T3-E1细胞的增殖并诱导其凋亡。 Dex可能会减弱成骨细胞的分化。 Dex处理后细胞内ROS水平显著增加。Dex通过下调p-PI3K和p-AKT的表达抑制成骨细胞和MC3T3-E1细胞中PI3K/AKT通路的激活。Dex处理后,成骨细胞和MC3T3-E1细胞中GSK3β的表达明显上调。通过降低Bax,裂解的caspase 3,裂解的caspase 9的表达和增加Bcl-2的表达,抑制GSK3β减轻Dex诱导的成骨细胞和MC3T3-E1细胞凋亡。

总之,该研究证实,Dex通过ROS-PI3K/AKT/GSK3β信号通路诱导成骨细胞凋亡。

原始出处:

Deng S, Dai G, et al., Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway. Biomed Pharmacother. 2019 Feb;110:602-608. doi: 10.1016/j.biopha.2018.11.103. Epub 2018 Dec 8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-04-19 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-04-02 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-08-27 xfpan20
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-11-07 anminleiryan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-09-22 lidong40
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
    2019-12-21 sunylz
  9. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1787580, encodeId=f1e41e8758066, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 19 18:36:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996266, encodeId=7aa0199626664, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Apr 02 23:36:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908515, encodeId=c9371908515fc, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Dec 31 22:36:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656177, encodeId=f17216561e710, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Aug 27 12:36:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085142, encodeId=07392085142a3, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 09:36:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024150, encodeId=dab62024150b9, content=<a href='/topic/show?id=bbba14239f5' target=_blank style='color:#2F92EE;'>#PI3K/AKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14239, encryptionId=bbba14239f5, topicName=PI3K/AKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Sep 22 16:36:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935594, encodeId=0b6c1935594a6, content=<a href='/topic/show?id=09328293fb' target=_blank style='color:#2F92EE;'>#GSK3β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8293, encryptionId=09328293fb, topicName=GSK3β)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 08 04:36:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918521, encodeId=4229191852182, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 21 12:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333211, encodeId=b87d13332113d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340291, encodeId=c9131340291bf, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Feb 05 18:36:00 CST 2019, time=2019-02-05, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map